{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:47:28Z","timestamp":1788871648095,"version":"build-2803163510"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,1,5]],"date-time":"2015-01-05T00:00:00Z","timestamp":1420416000000},"content-version":"vor","delay-in-days":369,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"NIH","award":["U01 AI078410-01"],"award-info":[{"award-number":["U01 AI078410-01"]}]},{"name":"NIH","award":["P01 AI088610-01"],"award-info":[{"award-number":["P01 AI088610-01"]}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.virol.2013.10.007","type":"journal-article","created":{"date-parts":[[2013,11,12]],"date-time":"2013-11-12T07:45:51Z","timestamp":1384242351000},"page":"363-374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1\/V2 masking"],"prefix":"10.1016","volume":"448","author":[{"given":"Aidy","family":"Salomon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chavdar","family":"Krachmarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Honnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry S.","family":"Zingman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Sarlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslaw K.","family":"Gorny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Zolla-Pazner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2013.10.007_bib1","doi-asserted-by":"crossref","first-page":"803535","DOI":"10.1155\/2012\/803535","article-title":"Resistance of subtype C HIV-1 strains to anti-V3 loop antibodies","volume":"2012","author":"Almond","year":"2012","journal-title":"Adv. Virol."},{"key":"10.1016\/j.virol.2013.10.007_bib2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.virol.2012.12.010","article-title":"Cross-neutralizing activity of human anti-V3 monoclonal antibodies derived from non-B clade HIV-1 infected individuals","volume":"439","author":"Andrabi","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.virol.2013.10.007_bib3","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1128\/JVI.72.2.1497-1503.1998","article-title":"Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage","volume":"72","author":"Andre","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2013.10.007_bib4","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1089\/aid.1993.9.1209","article-title":"High antigenic cross-reactivity of the V3 consensus sequences of HIV-1 gp120","volume":"9","author":"Baillou","year":"1993","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.virol.2013.10.007_bib5","doi-asserted-by":"crossref","first-page":"9998","DOI":"10.1128\/JVI.05045-11","article-title":"Analysis of a clonal lineage of HIV-1 envelope V2\/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors","volume":"85","author":"Bonsignori","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2013.10.007_bib6","doi-asserted-by":"crossref","first-page":"6006","DOI":"10.1128\/jvi.68.9.6006-6013.1994","article-title":"Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization","volume":"68","author":"Bou-Habib","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2013.10.007_bib7","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1126\/science.7973652","article-title":"Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody","volume":"266","author":"Burton","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.virol.2013.10.007_bib8","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1089\/aid.1991.7.831","article-title":"High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas","volume":"7","author":"Carrow","year":"1991","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.virol.2013.10.007_bib9","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1006\/viro.1995.1016","article-title":"Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes","volume":"206","author":"Connor","year":"1995","journal-title":"Virology"},{"key":"10.1016\/j.virol.2013.10.007_bib10","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1128\/JVI.01743-08","article-title":"Human immunodeficiency virus type 2 (HIV-2)\/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma","volume":"83","author":"Davis","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2013.10.007_bib11","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.virol.2009.02.022","article-title":"High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination","volume":"387","author":"Davis","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.virol.2013.10.007_bib12","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1742-4690-7-82","article-title":"HIV-1 subtype distribution in the Gambia and the significant presence of CRF49_cpx, a novel circulating recombinant form","volume":"7","author":"de Silva","year":"2010","journal-title":"Retrovirology"},{"key":"10.1016\/j.virol.2013.10.007_bib13","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1126\/science.1093137","article-title":"Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission","volume":"303","author":"Derdeyn","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.virol.2013.10.007_bib14","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1126\/science.1070441","article-title":"Diversity considerations in HIV-1 vaccine selection","volume":"296","author":"Gaschen","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.virol.2013.10.007_bib15","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1128\/JVI.78.5.2394-2404.2004","article-title":"The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope","volume":"78","author":"Gorny","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2013.10.007_bib16","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1128\/JVI.79.8.5232-5237.2005","article-title":"Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles","volume":"79","author":"Gorny","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2013.10.007_bib17","doi-asserted-by":"crossref","first-page":"5114","DOI":"10.4049\/jimmunol.159.10.5114","article-title":"Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity","volume":"159","author":"Gorny","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/j.virol.2013.10.007_bib18","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.molimm.2008.09.005","article-title":"Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1","volume":"46","author":"Gorny","year":"2009","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.virol.2013.10.007_bib19","doi-asserted-by":"crossref","first-page":"9035","DOI":"10.1128\/JVI.76.18.9035-9045.2002","article-title":"Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades","volume":"76","author":"Gorny","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2013.10.007_bib20","doi-asserted-by":"crossref","first-page":"6865","DOI":"10.1128\/JVI.02202-05","article-title":"Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1","volume":"80","author":"Gorny","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2013.10.007_bib21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1089\/aid.2005.21.171","article-title":"V3: HIV's switch-hitter","volume":"21","author":"Hartley","year":"2005","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.virol.2013.10.007_bib22","doi-asserted-by":"crossref","first-page":"595","DOI":"10.4049\/jimmunol.169.1.595","article-title":"Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci","volume":"169","author":"He","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.virol.2013.10.007_bib23","doi-asserted-by":"crossref","first-page":"W13","DOI":"10.1097\/01.aids.0000247564.73009.bc","article-title":"Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004","volume":"20","author":"Hemelaar","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.virol.2013.10.007_bib24","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1126\/science.1905842","article-title":"Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1","volume":"253","author":"Hwang","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.virol.2013.10.007_bib25","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1126\/science.1703322","article-title":"Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1","volume":"250","author":"Javaherian","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.virol.2013.10.007_bib26","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/nsmb.1861","article-title":"Conserved structural elements in the V3 crown of HIV-1 gp120","volume":"17","author":"Jiang","year":"2010","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.virol.2013.10.007_bib27","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1128\/jvi.68.1.400-410.1994","article-title":"Presentation of native epitopes in the V1\/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains","volume":"68","author":"Kayman","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2013.10.007_bib28","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cell.2013.03.018","article-title":"Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization","volume":"153","author":"Klein","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.virol.2013.10.007_bib29","doi-asserted-by":"crossref","first-page":"6730","DOI":"10.1128\/jvi.68.10.6730-6744.1994","article-title":"Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1","volume":"68","author":"Korber","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2013.10.007_bib30","doi-asserted-by":"crossref","first-page":"10730","DOI":"10.1128\/JVI.00365-11","article-title":"Characterization of structural features and diversity of variable-region determinants of related quaternary epitopes recognized by human and rhesus macaque monoclonal antibodies possessing unusually potent neutralizing activities","volume":"85","author":"Krachmarov","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2013.10.007_bib31","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1128\/JVI.79.2.780-790.2005","article-title":"Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking","volume":"79","author":"Krachmarov","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2013.10.007_bib32","doi-asserted-by":"crossref","first-page":"7127","DOI":"10.1128\/JVI.02619-05","article-title":"Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1","volume":"80","author":"Krachmarov","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2013.10.007_bib33","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1089\/08892220152741432","article-title":"V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1","volume":"17","author":"Krachmarov","year":"2001","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.virol.2013.10.007_bib34","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1126\/science.2392685","article-title":"Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant","volume":"249","author":"LaRosa","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.virol.2013.10.007_bib35","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1128\/JVI.75.9.4165-4175.2001","article-title":"Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope","volume":"75","author":"Letvin","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2013.10.007_bib36","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1128\/JVI.80.3.1414-1426.2006","article-title":"Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants","volume":"80","author":"Li","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2013.10.007_bib37","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.virol.2010.04.010","article-title":"Subtype-specific conservation of isoleucine 309 in the envelope V3 domain is linked to immune evasion in subtype C HIV-1 infection","volume":"404","author":"Lynch","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.virol.2013.10.007_bib38","doi-asserted-by":"crossref","first-page":"12438","DOI":"10.1073\/pnas.1307382110","article-title":"Molecular architecture of the uncleaved HIV-1 envelope glycoprotein trimer","volume":"110","author":"Mao","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.virol.2013.10.007_bib39","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/nsmb.2351","article-title":"Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer","volume":"19","author":"Mao","year":"2012","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.virol.2013.10.007_bib40","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1128\/JVI.02658-10","article-title":"Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop","volume":"85","author":"Moore","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2013.10.007_bib41","doi-asserted-by":"crossref","first-page":"6913","DOI":"10.1073\/pnas.102562599","article-title":"Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes","volume":"99","author":"Moulard","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.virol.2013.10.007_bib42","doi-asserted-by":"crossref","first-page":"6642","DOI":"10.1128\/jvi.67.11.6642-6647.1993","article-title":"A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1","volume":"67","author":"Muster","year":"1993","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2013.10.007_bib43","doi-asserted-by":"crossref","first-page":"8098","DOI":"10.1128\/JVI.00966-10","article-title":"Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure\u2013function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1","volume":"84","author":"Pancera","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2013.10.007_bib44","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1128\/JVI.01444-07","article-title":"Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins","volume":"82","author":"Patel","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2013.10.007_bib45","doi-asserted-by":"crossref","first-page":"11483","DOI":"10.1073\/pnas.1004600107","article-title":"Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1","volume":"107","author":"Pejchal","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.virol.2013.10.007_bib46","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1128\/JVI.78.10.5205-5215.2004","article-title":"The V1\/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection","volume":"78","author":"Pinter","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2013.10.007_bib47","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1089\/aid.1993.9.985","article-title":"A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates","volume":"9","author":"Pinter","year":"1993","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.virol.2013.10.007_bib48","doi-asserted-by":"crossref","first-page":"5692","DOI":"10.1128\/jvi.67.9.5692-5697.1993","article-title":"Conformational changes affecting the V3 and CD4-binding domains of human immunodeficiency virus type 1 gp120 associated with env processing and with binding of ligands to these sites","volume":"67","author":"Pinter","year":"1993","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2013.10.007_bib49","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3233\/HAB-2005-143-408","article-title":"High frequencies of antibody responses to CD4 induced epitopes in HIV infected patients started on HAART during acute infection","volume":"14","author":"Robinson","year":"2005","journal-title":"Hum. Antibodies"},{"key":"10.1016\/j.virol.2013.10.007_bib50","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1128\/JVI.01839-06","article-title":"Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection","volume":"81","author":"Rong","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2013.10.007_bib51","doi-asserted-by":"crossref","first-page":"9434","DOI":"10.1073\/pnas.89.20.9434","article-title":"Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1","volume":"89","author":"Shioda","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.virol.2013.10.007_bib52","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1128\/JVI.72.1.651-659.1998","article-title":"Human rhinovirus type 14:human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1","volume":"72","author":"Smith","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2013.10.007_bib53","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1006\/viro.1994.1575","article-title":"Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization","volume":"204","author":"Spear","year":"1994","journal-title":"Virology"},{"key":"10.1016\/j.virol.2013.10.007_bib54","doi-asserted-by":"crossref","first-page":"9855","DOI":"10.1128\/JVI.72.12.9855-9864.1998","article-title":"Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1","volume":"72","author":"Spenlehauer","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2013.10.007_bib55","doi-asserted-by":"crossref","first-page":"6093","DOI":"10.1128\/JVI.00205-06","article-title":"Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity","volume":"80","author":"Stanfield","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2013.10.007_bib56","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3233\/HAB-2005-143-404","article-title":"Structural studies of human HIV-1 V3 antibodies","volume":"14","author":"Stanfield","year":"2005","journal-title":"Hum. Antibodies"},{"key":"10.1016\/j.virol.2013.10.007_bib57","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1056\/NEJMra0706737","article-title":"The challenge of HIV-1 subtype diversity","volume":"358","author":"Taylor","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2013.10.007_bib58","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0923-2516(91)90010-Z","article-title":"A human monoclonal antibody against the CD4-binding site of HIV1 gp120 exhibits potent, broadly neutralizing activity","volume":"142","author":"Tilley","year":"1991","journal-title":"Res. Virol."},{"key":"10.1016\/j.virol.2013.10.007_bib59","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1128\/jvi.70.2.1100-1108.1996","article-title":"Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1","volume":"70","author":"Trkola","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2013.10.007_bib60","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1089\/aid.1995.11.1379","article-title":"Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1","volume":"11","author":"Vancott","year":"1995","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.virol.2013.10.007_bib61","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nature10373","article-title":"Broad neutralization coverage of HIV by multiple highly potent antibodies","volume":"477","author":"Walker","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.virol.2013.10.007_bib62","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1126\/science.1178746","article-title":"Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target","volume":"326","author":"Walker","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.virol.2013.10.007_bib63","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature01470","article-title":"Antibody neutralization and escape by HIV-1","volume":"422","author":"Wei","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.virol.2013.10.007_bib64","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1016\/j.vaccine.2006.03.083","article-title":"Cross-clade recognition and neutralization by the V3 region from clade C human immunodeficiency virus-1 envelope","volume":"24","author":"Wu","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2013.10.007_bib65","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1187659","article-title":"Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1","volume":"329","author":"Wu","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.virol.2013.10.007_bib66","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jmb.2003.09.055","article-title":"Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning","volume":"335","author":"Zhang","year":"2004","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.virol.2013.10.007_bib67","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1126\/science.1192819","article-title":"Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01","volume":"329","author":"Zhou","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.virol.2013.10.007_bib68","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.virol.2007.09.024","article-title":"Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope","volume":"372","author":"Zolla-Pazner","year":"2008","journal-title":"Virology"},{"key":"10.1016\/j.virol.2013.10.007_bib69","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1089\/aid.2004.20.1254","article-title":"The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1","volume":"20","author":"Zolla-Pazner","year":"2004","journal-title":"AIDS Res. Hum. Retroviruses"}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682213005679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682213005679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:24:43Z","timestamp":1758587083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682213005679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":69,"alternative-id":["S0042682213005679"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2013.10.007","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1\/V2 masking","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2013.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}